Cover Image
市場調查報告書

鼠疫 : 開發平台分析

Plague - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 245959
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
鼠疫 : 開發平台分析 Plague - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 70 Pages
簡介

鼠疫是由於鼠疫這種細菌所引起的傳染病。這個細菌主要寄生在老鼠身上的跳蚤上。人類及其他動物接觸到老鼠及被跳蚤叮咬而感染。過去鼠疫曾經造成人類全體文明崩潰。現代由於生活水準的改善及抗生物質的進步,鼠疫終於成了一般疾病。鼠疫的一般症狀出現在腹股溝及腋下、頭部等腹股溝腺炎(淋巴結腫起、感到痛的所在)。鼠疫中罕見的嚴重情況,會侵襲肺部,並由人類互相傳染。

本報告提供全球各國治療鼠疫所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

鼠疫概要

治療藥的開發

  • 鼠疫開發中產品:概要
  • 鼠疫開發中產品:比較分析

各企業開發中的鼠疫治療藥

大學/研究機關研究中的鼠疫治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

鼠疫治療藥:開發中的產品一覽(各企業)

鼠疫治療藥:研究中的產品一覽(大學/研究機關別)

鼠疫開發治療藥的企業

  • Aradigm Corporation
  • Grifols, S.A.
  • iBio, Inc.
  • Mucosis B.V.
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc.

鼠疫:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型
  • 各治療分類

藥物簡介

  • 炭疽菌·鼠疫菌疫苗
  • ARD-3100
  • 鹽酸hydrochloride
  • 鼠疫菌疫苗
  • 肺血小板疫苗
  • 鼠疫蛋白質酪胺酸磷酸酶 (YopH) 抑制劑
  • TP-271
  • 鼠疫菌疫苗

鼠疫治療藥:最新的藥物簡介

鼠疫治療藥:暫停開發的產品

鼠疫治療藥:開發中止的產品

鼠疫相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8273IDB

Summary

Global Markets Direct's, 'Plague - Pipeline Review, H2 2016', provides an overview of the Plague pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Plague, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plague and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Plague
  • The report reviews pipeline therapeutics for Plague by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Plague therapeutics and enlists all their major and minor projects
  • The report assesses Plague therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Plague

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Plague
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Plague pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Plague Overview
  • Therapeutics Development
    • Pipeline Products for Plague - Overview
    • Pipeline Products for Plague - Comparative Analysis
  • Plague - Therapeutics under Development by Companies
  • Plague - Therapeutics under Investigation by Universities/Institutes
  • Plague - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Plague - Products under Development by Companies
  • Plague - Products under Investigation by Universities/Institutes
  • Plague - Companies Involved in Therapeutics Development
    • Aradigm Corporation
    • AvidBiotics Corp.
    • Endacea, Inc.
    • Grifols, S.A.
    • iBio, Inc.
    • Mucosis B.V.
    • Syntiron LLC
    • Takeda Pharmaceutical Company Limited
    • Tetraphase Pharmaceuticals Inc.
  • Plague - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (plague + small pox) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anthrax + plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-3100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-3150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ciprofloxacin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-97-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pneumonic plaque vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Pneumonic Plague - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Yoph Protein Tyrosine Phosphatase for Plague - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-271 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Yersinia pestis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Plague - Dormant Projects
  • Plague - Discontinued Products
  • Plague - Product Development Milestones
    • Featured News & Press Releases
      • Nov 19, 2012: UK Scientists Report On Efficacy Of Aradigm's Lipoquin Against Pneumonic Plague
      • May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against Plague
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Plague, H2 2016
  • Number of Products under Development for Plague - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Plague - Pipeline by Aradigm Corporation, H2 2016
  • Plague - Pipeline by AvidBiotics Corp., H2 2016
  • Plague - Pipeline by Endacea, Inc., H2 2016
  • Plague - Pipeline by Grifols, S.A., H2 2016
  • Plague - Pipeline by iBio, Inc., H2 2016
  • Plague - Pipeline by Mucosis B.V., H2 2016
  • Plague - Pipeline by Syntiron LLC, H2 2016
  • Plague - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Plague - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Plague - Dormant Projects, H2 2016
  • Plague - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Plague, H2 2016
  • Number of Products under Development for Plague - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top